Advances in Endocrine
Therapies 2005
Novel treatments targets & therapeutic potential
19th
and 20th January 2005 - Workshop 18th January 2005
Kensington Marriott Hotel,
London
**** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST
YOURS TODAY ****
In such a wide reaching industry, it is important to
focus on key areas of progression. At this conference delegates will learn
about new developments in significant areas of the market, from diabetes and
obesity to cancer and hormone replacement therapies.
THEMES WILL
INCLUDE:
**New developments in diabetes - how can your company enter this
rapidly growing & changing market?
**Learn about new approaches to weight
loss & emerging therapies for metabolic diseases
**Advice on how your
company can become an industry leader in the market for infertility
drugs
**Improve your clinical trials for osteoporosis & learn about the
alternatives to HRT
**Achieve more efficient insulin delivery - optimise your
potential success
**Benefit from the best practice case studies: Forteo;
Passport; Somatostatin
KEY SPEAKERS
**Dr. Anthony Beardsworth, Lead
Physician, Primary Care, Eli Lilly
**Dr. Monique Berwaer, Head, Metabolic
Diseases, Johnson & Johnson
**Caroline Turnbull, Armidex Brand Leader,
AstraZeneca
**Dr. Desmond Thompson, Senior Scientific Director,
Merck
**Dr. Milan Zdravkovic, International Medical Officer,
NovoNordisk
**Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy
and Business Development, Roche
**Dr. Bharat Tewarie, Executive Vice
President, Reproductive Health, Serono
**Dr. Eric Tomlinson, Chief Executive
Officer, Altea Therapeutics
**Dr. George Merriam, Scientific Advisor,
Theratechnologies
**Dr. Gerald Bernstein, Vice President, Medical Affairs,
Generex Biotechnology
**Dr. Alan Davis, European Medical Director,
Kendle
------------------
WHO SHOULD
ATTEND
------------------
**Vice President, Global Medical
Endocrinology
**Senior Vice President, Endocrine Business
**Senior Medical
Director, Endocrinology
**Director, Endocrinology &
Metabolism
**Senior Director, Metabolic Diseases
**Global Head, Diabetes
& Clinical Research
**Vice President, Diabetes
**Vice President,
Glucose Monitoring Systems
**Vice President, Cardiovascular &
Metabolism
**Executive Vice President, Women's Health
**Vice President,
Reproductive
Health
==================================================================
This
event will also feature: Pre-conference Interactive
Workshop
==================================================================
Glucose
Sensing & Insulin Pumps
Workshop leaders: Ian Tilly, Glucose Sensor
Specialist, Medtronic MiniMed Uk &
Ireland
Susan Judge, Diabetes Specialist,
Nurse & Education Co-ordinator.
Strategies for pricing and market
access of innovative endocrine therapies
Led by: Christian Schuler, Director
Health Sciences Division, Simon-Kucher &
Partners
---------------------
DELEGATE
REGISTRATION
---------------------
Places at this event are strictly
limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please
contact me via phone or email. Book early to secure a place.
- PRICING
-
Attend the:
2 Day conference with interactive workshop - ONLY
GBP1600 plus VAT
2 Day conference - ONLY GBP1299 plus VAT
Workshop only -
ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact
me:
Joe Stone
Account Manager -
Conference Division
Visiongain B2B Conferences
Tel. +44(0)20 8767
6711
Fax. +44(0)20 8767 5001
mailto:joe.stone@visiongain.com
B2B Conferences is part of the Visiongain Group
**** FULL
CONFERENCE AGENDA BELOW
****
===================================
PRE-CONFERENCE INTERACTIVE
WORKSHOP
Tuesday 18th January
2005
===================================
Glucose sensing & insulin
pumps:
optimise diabetes care & analyse pump therapy
Led by: Ian
Tilly, Glucose Sensor Specialist & Susan Judge,
Diabetes Specialist,
Nurse & Education Co-ordinator,
Medronic MiniMed UK &
Ireland
Main topics of discussion:
. Validation of new treatment
efficacy in improving
glycaemic control.
. Enhancing the value of
clinical trials.
. Features and benefits of insulin pump therapy.
.
Combining sensors & pumps - creating an artificial
pancreas.
Strategies for pricing and market access of innovative
endocrine therapies
Led by: Christian Schuler, Director Health Sciences
Division, Simon-Kucher & Partners
Strategies for Pricing and Market
Access of Innovative
Endocrine Therapies
. Challenges within the endocrine
market environment
. P&R Environment for innovative endocrine
therapies
. Key learnings from recent product launches
. The concept of
value based pricing
. Pricing
techniques
===================================
Day One Wednesday 19th
January 2005
===================================
09:00 Registration
and coffee
09:30 Opening remarks from the chair
09:40 An Overview
of the Industry
Dr. Ray Scraggs, Head Consultant at visiongain, will
introduce
questionnaires which give you the chance to make comments
on the
Endocrine Industry. The findings will be discussed at
the end of the day in a
panel session.
NEW DEVELOPMENTS IN DIABETES
09:50 The Future of
the Diabetes Market: What are the
Possibilities for Your Company?
. How to
rise to the challenge for advanced and effective treatment
. Impaired
metabolism: how to cope with complications
. Tactics for novel target
discovery
. Strategies for genomics based drug discovery
. Tips on
improving diabetes care - decrease complications and gain
metabolic
control
. How to avoid microvascular complications
. Different approaches
to post infection therapies
Dr. Manfred Ganz, Director, Head of Medical
Assessment Strategy and
Business Development Global Diabetes Care
Roche
Diagnostics GmbH
10:30 CASE STUDY: 11 bHSD1 - A Novel Target in the
treatment of
Diabetes & Metablic Symdrome
. The potential of selective
11 bHSD1 inhibition in the treatment of
diabetes and associated
complications
. The need for a better understanding of the endocrine function
of
adipose tissue
. Cortisol induced insulin resistance in man
.
HSD1 and metabolic syndrome: what are the possibilities for your
company?
. Effect of selective HSD1 inhibition in diabetic rodents: analysis
of
results
. The importance of 11beta-HSD1 in the development of
metabolic
syndrome - examination of data from studies of obese
rodents
Dr. Monique Berwaer, Head, Metabolic Diseases
Johnson &
Johnson
11:10 Morning Coffee
11:30 CASE STUDY: Incretin Mimetics -
GLP-1 and Liraglutide
. Mechanism of action: increasing insulin secretion;
reducing
glucagon production; delaying gastric emptying
. What are
the potential applications?
. Possible multiple benefits including weight
loss vs drawbacks of
delivery by injection
. Analysis of results of
preclinical testing
. Potential for sustained action - improving patient
care
Dr. Milan Zdravkovic, International Medical Officer
Novo
Nordisk
12:10 Innovations in Insulin Delivery: Possibilities for
New
Technologies
. What will be the future of the insulin pill? -
replacing first phase
insulin response
. Recent advances in insulin
pump therapy - analysis of new
possibilities & assessment of
options
. The impact of oral insulin spray on the market
. Updates on FDA
approval for inhaled insulin: overcoming long
term effects
Dr.
Gerald Bernstein, Vice President, Medical Affairs
Generex
Biotechnology
12:50 Lunch
14:00 CASE STUDY: Passport - The
Potential for Transdermal Insulin
Delivery
. Mechanism of action: a sonic
applicator deploying
. ultrasound & introducing drug molecules through
the skin
Added benefits of combined skin patch and insulin pill
.
Increasing administration length: new development of a 24 hour
patch
. Advantages over alternatives - achieve steady and accurate
delivery of your diabetes drugs
. Improve patient compliance - a
non-invasive, pain and hassle free
treatment
. Market potential - a
cost-effective, efficient treatment without
troublesome
side-effects
Dr. Eric Tomlinson, Chief Executive Officer
Altea
Therapeutics
NOVEL TREATMENTS IN THE OBESITY MARKET
14:40 New
Approaches to Weight Loss Drugs: Responding to Gaps
in the Obesity
Market
. Current drugs and their limitations: lessons to be learnt from
the
past
. How can body weight be regulated and modified?
. New
approaches for discovering novel targets for the treatment of
obesity
Jon Arch, Professorial Research Fellow, Deputy Director of Metabolic
Research
University of Buckingham
15:20 Afternoon Tea
THE
ENDOCRINE TREATMENT OF BREAST CANCER
15:40 CASE STUDY: Armidex - the
Future of Treatment &
Prevention of Breast Cancer
. The first
aromatase inhibitor to be approved - effect on your
market
.
Current market for breast cancer drugs - where can you capture a
share?
. Developments in endocrine agents: steps towards the goal
of
breast cancer prevention
. Comparison of aromatase inhibitors
with tamoxifen - how long
before tamoxifen is obsolete?
. Analysis
of results of recent clinical studies
Caroline Turnbull, Arimidex Brand
Leader
AstraZeneca
16:20 Questions and Discussion
16:30
Summation of day one from conference chair
16:40 Close of Day
One
==================================
Day Two Thursday 20th January
2005
==================================
08:30 Registration and
Coffee
09:00 Opening remarks from the Chair
DEVELOPMENTS IN GROWTH
HORMONE THERAPIES
09:10 KEYNOTE SESSION
MINI SYMPOSIUM: GROWTH
HORMONECLINICAL INSIGHTS & MECHANISMS
With invited manufacturers of
growth hormone and growth
hormone secretagogues
Led By: Dr. George
Merriam
Scientific Advisor, Professor of Medicine
Theratechnologies,
University of Washington
10:10 CASE STUDY: Somatostatin - Developments in
the Treatment
of Acromegaly
. Mechanism of action of somatostatin
analogues
. The need to improve clinical management of patients
.
Addressing patient issues: appropriate dosing regimes & extended
duration preparations
. Defining the role of somatostatin analogues: checking
& balancing
hormones & growth
. Advantages of multiple
benefits: treating adverse clinical effects
of acromegaly
. SOM230:
a new multiligand somatoststatin analogue - the
possibilities for
future treatments
Dr. Herbert Schmid, Senior Research Investigator for
Somatostatin Research
Novartis
10:50 Morning
Coffee
ENDOCRINOLOGY AND WOMEN'S HEALTH ISSUES
11:10 The
Endocrinology Of Ageing
. Ageing - the major driver in the endocrine
industry: gain your share
of the market
. The underlying mechanisms
responsible for reduction in strength,
frequency and production of
hormones
. Future targets for age-related diseases: what are the
opportunities
for your company?
Dr. Desmond Thompson, Senior
Scientific Director
Merck
11:50 Delivering Clinical Trials for
Osteoporosis: Improve your
Company's Studies
. Clinical trial metrics
& management: ensure your osteoporosis trials
are efficient &
cost effective
. Tips for long & short term studies
. Advice on
recruiting & retaining trial subjects
. How to select appropriate
clinical endpoints for your osteoporosis
trials
. Safety
assessments & regulatory requirements: how do they affect
your
studies?
Dr. Alan Davies, European Medical Director
Kendle
12:30
Lunch
14:00 CASE STUDY: Forteo - The First Bone Formation Agent in
the
Treatment of Osteoporosis
. Mechanism of action: the use of
recombinant human parathyroid
hormone: the potential to replace
depleted bone stores
. Multiple benefits: forming new bone, increasing bone
density
and improving bone strength
. Overcoming possible side
effects - what can be done to improve
patient care?
. The proven
success of Forteo: results from the fracture
prevention trial
.
Launch in India - tracking the success
Dr. Anthony Beardsworth, Lead
Physician, Primary Care
Eli Lilly
14:40 CASE STUDY: Microencapsulated
r-FSH - Novel Treatments
for Infertility
. The growing market for the
treatment of infertility - tips for market
share
. Learn from the
experts - how Serono became market leaders for
the treatment of
infertility with Gonal-F
. Gonal-f(R) RFF Pen: the first and only prefilled
and ready-to-use
multi-dose FSH in the US
. Benefits of rFSH over
urinary products - consistent potency & less
contaminants
.
Analysis and updates of recent clinical trials
. Future targets for the
treatment of infertility
Dr. Bharat Tewarie, Executive Vice-President,
Reproductive Health
Serono
15:20 Afternoon Tea
RECENT ADVANCES
IN HYPERTENSION
16:00 CASE STUDY: SPP100 (Aliskiren) - A Novel Treatment
for
Hypertension & Related Conditions
. A new mode of action for the
treatment of hypertension & end
organ damage
. Analysis of
results of recent clinical trials & studies: Aliskiren Vs
Irbesartan
. New technical achievements: producing a commercially
viable
manufacturing process
. Possibilites for multiple treatment
benefits
Dr. Hans Brunner, Medical Advisor
Speedel
16:40
DISCUSSION: Attendees Perspective
Presentation and discussion of the
questionnaire results led by Dr. Ray
Scraggs. This will involve some freeform
discussion & the opportunity
to engage in knowledge sharing with fellow
professionals.
17:00 Chairman summation and close of
conference
Terms & Conditions
NB - Due to high
demand, we do not 'reserve' or 'hold' places - a request for an invoice to be
raised will be treated as an official booking and will be subject to the
cancellation policy as outlined below.
Cancellations/substitutions and name
changes: All bookings carry a 50% liability after the booking has been made, by
post fax, email or web. There will be no refunds for cancellations received on
or after one month before the start of the conference (e.g. cancellation on or
after 20th January for a conference starting on 20th February). If you decide to
cancel after this date the full invoice remains payable. Conference notes, which
are available on the day, will be sent to you. Unfortunately we are not able to
transfer places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any time
as long as we are informed in writing by e-mail, fax or post. Name changes and
substitutions must be from the same company and are not transferable between
companies or countries.
Indemnity: visiongain Ltd reserve the right to
change the conference/executive briefing content, timing, speakers or venue
without notice. The event may be postponed or cancelled due to acts of
terrorism, war, extreme weather conditions, industrial action, acts of God or
any event beyond the control of visiongain Ltd. If such a situation arises we
will endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the cost
of the registration, travel and expenses.
To unsubscribe please reply
with unsubscribe in the subject line.
Data protection: Visiongain Ltd
gathers and manages data in accordance with the Data Protection Act 1998.
Information contained about you may be used to update you on visiongain Ltd
products and services via post, telephone, fax or email, unless you state
otherwise. If you wish your details to be amended, please send your request to
the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG.
Alternatively please reply with unsubscribe in the subject line. Please allow
approximately 7 days for your removal or update request, you may receive
additional pieces of communication from visiongain Ltd during the transitional
period, whilst the changes come into effect.